Found: 33
Select item for more details and to access through your institution.
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 3, p. 281, doi. 10.1002/cpdd.650
- By:
- Publication type:
- Article
Acquired Left Ventricular-Right Atrial Communication Gerbode-Type Defect.
- Published in:
- Echocardiography, 2002, v. 19, n. 1, p. 67, doi. 10.1046/j.1540-8175.2002.00067.x
- By:
- Publication type:
- Article
Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 1, p. 98, doi. 10.1111/dom.12788
- By:
- Publication type:
- Article
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
- Published in:
- European Heart Journal, 2019, v. 40, n. 33, p. 2775, doi. 10.1093/eurheartj/ehy862
- By:
- Publication type:
- Article
Development and preliminary validation of a Function IndeX for Trauma (FIX-IT).
- Published in:
- 2013
- By:
- Publication type:
- journal article
Development and preliminary validation of a Function IndeX for Trauma (FIX-IT).
- Published in:
- Canadian Journal of Surgery, 2013, v. 56, n. 5, p. E114, doi. 10.1503/cjs.004312
- By:
- Publication type:
- Article
Corrigendum to ‘Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity–mortality trial’ [Eur J Heart Fail 2009;11:795–801].
- Published in:
- 2010
- By:
- Publication type:
- Correction Notice
The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure.
- Published in:
- European Journal of Heart Failure, 2009, v. 11, n. 11, p. 1071, doi. 10.1093/eurjhf/hfp130
- By:
- Publication type:
- Article
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity–mortality trial.
- Published in:
- European Journal of Heart Failure, 2009, v. 11, n. 8, p. 795, doi. 10.1093/eurjhf/hfp098
- By:
- Publication type:
- Article
Psychometric properties of a Swedish version of the Kansas City Cardiomyopathy Questionnaire in a Chronic Heart Failure population
- Published in:
- European Journal of Cardiovascular Nursing, 2008, v. 7, n. 3, p. 214, doi. 10.1016/j.ejcnurse.2007.08.005
- By:
- Publication type:
- Article
Psychometric properties of a Swedish version of the Kansas City Cardiomyopathy Questionnaire — A method to detect symptoms in a chronic heart failure population
- Published in:
- 2008
- By:
- Publication type:
- Abstract
Adaptation of the endothelium to fluid flow: in vitro analyses of gene expression and in vivo implications.
- Published in:
- Vascular Medicine, 2004, v. 9, n. 1, p. 35, doi. 10.1191/1358863x04vm521ra
- By:
- Publication type:
- Article
Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies.
- Published in:
- Clinical Cardiology, 2018, v. 41, n. 10, p. 1328, doi. 10.1002/clc.23049
- By:
- Publication type:
- Article
Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial
- Published in:
- Clinical Cardiology, 2017, v. 40, n. 2, p. 59, doi. 10.1002/clc.22678
- By:
- Publication type:
- Article
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti- PCSK9 Antibody in Statin-Intolerant Subjects 3 ( GAUSS-3) Trial.
- Published in:
- Clinical Cardiology, 2016, v. 39, n. 3, p. 137, doi. 10.1002/clc.22518
- By:
- Publication type:
- Article
Rationale and Design of LAPLACE-2: A Phase 3, Randomized, Double-Blind, Placebo- and Ezetimibe-Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy.
- Published in:
- Clinical Cardiology, 2014, v. 37, n. 4, p. 195, doi. 10.1002/clc.22252
- By:
- Publication type:
- Article
Design and Rationale of the GAUSS-2 Study Trial: A Double-Blind, Ezetimibe-Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab ( AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy.
- Published in:
- Clinical Cardiology, 2014, v. 37, n. 3, p. 131, doi. 10.1002/clc.22248
- By:
- Publication type:
- Article
Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy.
- Published in:
- Clinical Cardiology, 2012, v. 35, n. 7, p. 385, doi. 10.1002/clc.22014
- By:
- Publication type:
- Article
Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients.
- Published in:
- JAMA: Journal of the American Medical Association, 2016, v. 316, n. 22, p. 2373, doi. 10.1001/jama.2016.16951
- By:
- Publication type:
- Article
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 4, p. 513, doi. 10.1002/jcph.832
- By:
- Publication type:
- Article
Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2018, v. 45, n. 3, p. 505, doi. 10.1007/s10928-018-9592-y
- By:
- Publication type:
- Article
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 5, p. 616, doi. 10.1002/jcph.840
- By:
- Publication type:
- Article
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Effect of Evolocumab or Ezetimibe Added to Moderate-or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 311, n. 18, p. 1870, doi. 10.1001/jama.2014.4030
- By:
- Publication type:
- Article
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients.
- Published in:
- JAMA: Journal of the American Medical Association, 2012, v. 308, n. 23, p. 2497, doi. 10.1001/jama.2012.25790
- By:
- Publication type:
- Article
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
- Published in:
- European Heart Journal, 2018, v. 39, n. 27, p. 2577, doi. 10.1093/eurheartj/ehy122
- By:
- Publication type:
- Article
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.
- Published in:
- European Heart Journal, 2014, v. 35, n. 33, p. 2249
- By:
- Publication type:
- Article